Bangla Desh - anglès - DGDA (Directorate General of Drug Administration)

super power pharmaceuticals ltd. - sulphanilamide - powder - 100 %

Bangla Desh - anglès - DGDA (Directorate General of Drug Administration)

techno drugs ltd. - sulphanilamide - powder - 100 %

Bangla Desh - anglès - DGDA (Directorate General of Drug Administration)

one pharma ltd. - sulphanilamide - powder - 100 %

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aspen medical products malaysia sdn bhd - busulphan -

Kenya - anglès - Pharmacy and Poisons Board

aspen pharmacare limited healthcare park, woodlands drive, woodmead - busulphan - tablet - 2mg - alkylating agents: alkyl sulfonates

Nova Zelanda - anglès - Ministry for Primary Industries

vetlife ltd - zinc oxide; sulphanilamide; calamine - zinc oxide 238 g/kg; sulphanilamide 119 g/kg; calamine 119 g/kg - antibiotic

Singapur - anglès - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - busulphan - tablet, film coated - 2 mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 100 mg - capsule, hard - excipient ingredients: macrogol 20000; titanium dioxide; gelatin; hypromellose; indigo carmine; erythrosine; maize starch; sucrose - sporanox is indicated for use in adults for the treatment of: superficial dermatomycoses not responding to topical treatment. fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. pityriasis versicolor not responding to any other treatment. vulvovaginal candidiasis not responding to topical treatment. oral candidiasis in immunocompromised patients. onychomycosis caused by dermatophytes. systemic mycoses: -systemic aspergillosis, histoplasmosis, sporotrichosis. -treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. -treatment of oropharyngeal and/or oesophageal candidiasis when fist line systemic antifungal therapy is inappropriate or has proven ineffective. -treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology,

Malta - anglès - Malta Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cefazolin sodium - powder for solution for injection/infusion - cefazolin sodium 1 g - antibacterials for systemic use

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - chlortetracycline; sulphanilamide - cutaneous spray, powder - 2.85, 50 gram/100gram - chlortetracycline, combinations - cattle, dogs, goats, horses, sheep - antibacterial